KYORIN Pharmaceutical Co.,Ltd. · TSE:4569
KYORIN Pharmaceutical Co.,Ltd — H1 FY2020 Earnings Presentation
32 slides from KYORIN Pharmaceutical Co.,Ltd's earnings presentation, Nov 6, 2020
Slide 1: Interim Term Financial Results Ended September 2020
Interim Term Financial Results Ended September 2020 November 6 , 2020 KYORIN Holdings, Inc. President Yutaka Ogihara
Slide 2: Agenda
➢ Outline of Consolidated Financial Results • Trends of mainstay products ➢ Consolidated Financial Forecast ➢ Status of R&D Pipeline ➢ Initiative toward realization of the long-term vision ”HOPE100” 1
Slide 3: Impact of COVID-19 on our Business
Impact of COVID-19 on our Business ■Promotion Activities etc. ●The spread of COVID-19 sets back sales progress ・Patient’s suppressive behavior to medical consultation diminishes KYORIN pharmaceutical’s main products market(exp. Respiratory, ENT, Pediatrics) ・Decrease of infected patients stagnated a
Slide 4: Outline of Consolidated Financial Results
Outline of Consolidated Financial Results 3
Slide 5: Outline of Consolidated Financial Results for the Interim Term Ended September 2020
Outline of Consolidated Financial Results for the Interim Term Ended September 2020 Change (forecast) (Units:¥billion) Sep/19 Sep/20 Change Change(%) Announced on May 12,2020 Net Sales 48.3 47.7 -0.6 -1.2 -5.1 Operating 0.8 1.5 +0.7 +91.7 -0.9 Income Ordinary 1.1 1.8 +0.7 +68.5 -0.8 Income Net Incom
Slide 6: Segment Sales and Breakdown of Gain and Loss
Segment Sales and Breakdown of Gain and Loss Change Change (forecast) (Units: ¥billion) Sep/19 Sep/20 Change Announced on (%) May 12,2020 Sales 48.3 47.7 -0.6 -1.2 -5.1 New ethical drugs, etc. 33.7 32.9 -0.8 -2.6 -3.9 (Japan) New ethical drugs(Overseas) 0.4 0.5 +0.1 +35.1 +0.2 Generic drugs 14.2 14.
Slide 7: Highlights of Business Performance: Net sales
Highlights of Business Performance:①Net sales (Units: ¥billion) 50 48.3 47.7 【Net Sales ¥-0.6bln】 New ethical drugs, etc.(Japan) 40 14.2 14.4 ¥-0.8bln ・New drugs "Beova" and "Desalex“ etc. grew ・Market slump and decrease in sales of long-listed 0.4 0.5 products (Nasonex, Kipres, Mucodyne etc.) ・Envi
Slide 8: Highlights of Business Performance: Operating Income
Highlights of Business Performance : ②Operating Income (Units:¥billion) 【Operating Income +¥0.7 bln】 1.5 1.5 Gross Profit increased +¥0.3 bln -0.5 Net Sales decreased:¥0.6 bln year on year ±0 Cost of sales ratio decreased 1.2% ・Product mix 1 0.8 +0.3 ・Effort to reduce costs(Raw material cost,etc) R&
Slide 9: Highlights of Business Performance: Change (forecast)
Highlights of Business Performance :③Change (forecast) Change (forecast) (Units:¥billion) Sep/19 Sep/20 Change Change(%) Announced on May 12,2020 Net Sales 48.3 47.7 -0.6 -1.2 -5.1 New ethical drugs, etc.(Japan) 33.7 32.9 -0.8 -2.6 -3.9 New ethical drugs (Overseas) 0.4 0.5 +0.1 +35.1 +0.2 Generic dr
Slide 10: Main Product Sales Update
Main Product Sales Update (単位:億円) Change (forecast) Sep/19 Sep/20 Change Change(%) Announced on May 12,2020 Flutiform (Combination drug for asthma treatment) 6.7 6.4 -0.3 -5.6 -0.6 Desalex (Antiallergic Agent) 0 1.8 +1.8 - -1.3 Beova (β3 adrenergic receptor agonist overactive bladder therapeutics )
Slide 11: Trends of mainstay products and Generic drugs
Trends of mainstay products and Generic drugs 10
Slide 12: Change of ethical drug market and number of patients
Change of ethical drug market and number of patients (First half of the fiscal year ending Mar.2021) Ethical Drug Market in 2020 (Units:¥ bln) (Unit:%) 102.4 101.8 1000 95.7 93.5 95.5 100 Status in first half 2020 87.3 ■Ethical drug market 800 80 ・Market side gradually recovered 600 60 ■Patients 1,0
Slide 13: Main Product Flutiform (Anti-asthmatic)
■Main Product Flutiform(Anti-asthmatic) sales (Units:bln) (Unit:%) (Units:bln) ICS/LABA market Flutiform YonY 16 14.6 15.0 12 100.2% 14.5 100 14 13.1 10 83.8 83.2 84.9 11.9 75.3 75.6 12 2nd 80 10.1 7.9 8.2 7.9 half 8 10 7.0 6.5 60 8 6 11.3 5.5 bln 6 8.4 40 4 7.6 8.2 7.8 7.8 4 1st 6.1 6.7 6.4 7.0 hal
Slide 14: Main Product Beova/Uritos (OAB)
■Main Product Beova/Uritos(OAB) OAB market YonY Sales 113.6% (Units:bln) (Unit:%) (Units:bln) Beova 108.8 107.4 8 12 7.3 99.9 99.8 7.0 93.2 100 10 6 10.3 3.5 2nd bln 80 3.5 half 8 4.3 7.9 8.1 4 7.2 7.5 7.4 60 6 3.7 40 2 3.8 1st 4 3.5 5.6 half bln 4.5 4.7 4.4 4.4 20 0.7 0.6 2 4.0 0 17/3 18/3 19/3 20/
Slide 15: Main Product Desalex (Antiallergic Agent)
■Main Product Desalex(Antiallergic Agent) Sales (Units:bln) Antihistamine market (Unit:%) (Units:bln) Desalex 8.8 YonY 15 98.8 8 7.5 88.4 100 81.6% 84.4 84.9 78.4 80 6 5.6 2nd 10 half 4.9 15.2 60 5.6 bln 4 3.7 0.9 5 10.0 40 4.0 9.3 9.1 8.6 8.5 2 20 2.8 2.6 3.1 1st 1.8 half 1.0 0.9 0 0 0 0 Apr May Ju
Slide 16: Main Product Lasvic (Oral new quinolone antibacterial agent)
■Main Product Lasvic(Oral new quinolone synthetic antibacterial agent) YonY Sales ◆ market (Units:bln) Oral antimicrobial market quinolone (Unit:%) (Units:bln) Lasvic 5 6.7bln 4.1 6 5.5 100 4 4.7 4.9 4.9 80 69.5% 4.0 3 4 2nd 68.5 60 2.6 half 48.1 61.3 65.7 65.5 62.9% 55.4 2 1.7 53.1 52.4 40 47.2 2 3
Slide 17: Status of Generic Drugs
■Status of Generic Drugs Sales (Units:bln) Generic Drugs 34.9 35 33.0 31.0 29.3 30 27.7 25.0 25 19.3 2nd 16.8 18.6 half ◼Status in first half 2020 15.7 20 14.7 Action for an authorized generic drug(AG) 14.7 ●Montelukast AG(for Adult)Keep >50% share in GE market 15 (¥4.5bln) 1st ●Mometasone AG expand
Slide 18: Consolidated Financial Forecast
Consolidated Financial Forecast 17
Slide 19: Consolidated Financial Forecast in FY2020
Consolidated Financial Forecast in FY2020 Versus the FY 2020 YoY FY2020 revised forecast (Units:¥billion) FY2019 (revised (Original forecast) Change Change(%) forecast) Change Net sales 110.0 108.0 -2.0 -1.8 115.5 -7.5 New ethical drugs, 77.5 73.8 -3.7 -4.8 79.7 -5.9 etc.(Japan) New ethical drugs 1.
Slide 20: Forecast of Mainstay Products Sales
Forecast of Mainstay Products Sales Versus the FY2020 YoY FY2020 revised (Units:¥billion) FY2019 (Revised (Original forecast forecast) Change Change(%) forecast) Change Flutiform (Combination drug for asthma treatment) 14.6 14.5 -0.1 -0.5 15.0 -0.5 Desalex (Antiallergic Agent) 2.6 7.5 +4.9 +191.1 8.
Slide 21: Shareholder Returns
Shareholder Returns Basic Policy ・While maintaining the sound financial base, we aim to improve the capital efficacy through growth investment and returns to shareholders ・We will maintain stable dividends taking DOE(Dividend On Equity ratio) into account. Dividend FY2020 FY2018 FY2019 (forecast) Di
Slide 22: Status of R&D Pipeline
_Kyorin @ Status of R&D Pipeline
Slide 23: Drug Development Pipeline (as of May)
Drug Development Pipeline Schedule in FY2020 (As of May 12 announcement) Development Code PhⅠ PhⅡ PhⅢ Application Approval/ Launch End of the PhⅠ/PhⅡ Ad-SGE-REIC PhⅡStart 2018/6 Respir Expected atory KRP-108P 2019/7 launch in FY 2020 Expected KRP-R120 clinical trial in FY 2020 Expected Infection KRP
Slide 24: Drug Development Pipeline (as of Nov. 5)
Drug Development Pipeline Schedule in 2020 ※Progress in 2020(as of Nov.5) Development Code PhⅠ PhⅡ PhⅢ Application Approval/ Launch 2019/7 Approved KRP-108P in June Respir atory KRP-R120 2020/7 Expected Infection KRP-AM1977Y 2019/10 launch in FY 2020 Expected Urology KRP-116D 2020/3 launch in FY 202
Slide 25: Development pipeline aiming for approval in FY2020
Development pipeline aiming for approval in FY2020 Combination drug for asthma treatment “KRP-108P” ■Approved(Jun.2020) Study results: PhⅢ study confirmed non-inferiority to control drug (fluticasone / salmeterol combination) Efficacy and safety for patients with bronchial asthma aged ≥ 5, < 16 year
Slide 26: Initiatives toward realization of the long-term vision HOPE 100
Initiatives toward realization of the long-term vision “HOPE 100” 25
Slide 27: Outline of New Medium-Term Business Plan HOPE 100-Stage 3-
Outline of New Medium-Term Business Plan “HOPE 100-Stage 3-” 【Statement】 “Realize growth trend by pursuing Kyorin’s originality” ・Shift to business based on the proposal of solutions and accelerate the growth of new drug groups. ・ Enhance pipeline to support medium-term growth Business Strategy ・ St
Slide 28: Solution Provision Activities in Infection Domain
Shift to business based on the proposal of solutions and accelerate the growth of new drug groups Solution Provision Activities in Infection Domain Response to changing environment (MR activities/Medical care provision system) Aim for launch in FY2020 Rebuild sales structure and enhance details ・KRP
Slide 29: Interstitial lung disease KRP-R120
Enhance pipeline to support medium-term growth Interstitial lung disease “KRP-R120” Clinical trial of KRP-R120(Started Ph1 study) ■Contract:license to develop and commercialize in Japan with aTyr pharma (USA) (Jan.2020) ■Development status:Ph1 study(started in Jul.2020) ■Therapy area:Interstitial lu
Slide 30: Treatment agent for BPH AKP-009
Enhance pipeline to support medium-term growth Treatment agent for BPH “AKP-009” Joint Development and Commercialization Agreement for a treatment agent for Benign Prostatic Hyperplasia with ASKA Pharmaceutical ■Contract:Sep.2020(Press release 30/Sep) ■Contract contents ・ We were granted the joint d
Slide 31: Active partnering activities
Expand overseas revenue Active partnering activities License agreement with Otonomy,Inc.(USA) regarding novel candidate compound ■Mode of action It helps improve hearing function in patients with sensorineural hearing loss by regenerating cochlear hair cells to replace cells damaged due to noise exp
Slide 32: Kyorin ©)
Kyorin ©) Kyorin ©)